title: The New Era of Hepatitis C: Therapy in Liver Transplant Recipients.
abstract: Hepatitis C virus (HCV) is the leading cause of end-stage liver disease in both Europe and the United States and is the most common reason for liver transplant. In the absence of antiviral therapy, recurrent infection is the norm with subsequent graft hepatitis and impaired survival. Whether it may be better to postpone therapy in patients in whom higher risk of failure and toxicity is coupled with lower chance of liver function improvement likely depends on several factors, including waiting time, center allocation policy, presence of hepatocellular carcinoma and local prevalence of anti-HCV-positive donors.
authors.affiliation: Banner Transplant Institute, 1441 North 12th Street, Second floor, Phoenix, AZ 85006, USA; Banner University Medical Center Phoenix, Phoenix, AZ, USA.
authors.forename: Ester Coelho
authors.initials: EC
authors.lastname: Little
authors.affiliation: Servicio de Medicina Digestivo (Torre F-5), La Fe University Hospital, Ciberehd*, University of Valencia, Avda Fernando Abril Martorell n 106, Valencia 46026, Spain. Electronic address: marina.berenguer@uv.es.
authors.forename: Marina
authors.initials: M
authors.lastname: Berenguer
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D058625:End Stage Liver Disease / Q000601:surgery*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents
keywords: Anti-HCV–positive donors; Cirrhosis; Direct antiviral agents; Drug-drug interactions; Hepatitis C virus; Hepatocellular carcinoma; Liver transplant; Waiting list